EGFR-TKIs have been revealed to counteract these effects by enhancing MHC class I and II antigen presentation in response to IFN-γ, increasing levels of CD8+ T cells and DCs, reducing FOXP3+ Tregs, inhibiting the polarization of macrophages to the immunosuppressive M2 phenotype, and lowering PD-L1 expression on tumor cells. The gene discussed is CD8A; the disease is neoplasm.